Home > News > Kereos' Collaborators Present on Targeted Therapies
November 15th, 2005
Kereos' Collaborators Present on Targeted Therapies
Abstract:
Kereos, a biotechnology company developing targeted imaging agents and therapeutics to improve the detection and treatment of cancer and cardiovascular disease, announced today that the company's collaborators at Washington University School of Medicine will be presenting preclinical data on two therapeutic candidates at the American Heart Association (AHA) Scientific Sessions this week. These agents are the first cardiovascular-targeted therapeutics in Kereos' pipeline of ligand-targeted emulsions, and represent two of the first applications of nanotechnology to treating cardiovascular disease.
Source:
prnewswire
Bookmark:
| Related News Press |
Possible Futures
Organic solar cells reach record efficiency, benchmark for commercialization April 23rd, 2018
Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018
New qubit now works without breaks: A universal design for superconducting qubits has been created April 19th, 2018
Observing biological nanotransporters: Chemistry April 19th, 2018
Nanomedicine
Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018
Observing biological nanotransporters: Chemistry April 19th, 2018
Nanobiotix Shows NBTXR3 Nanoparticles Can Stoke Anti-Tumor Immune Response April 17th, 2018
Announcements
Organic solar cells reach record efficiency, benchmark for commercialization April 23rd, 2018
Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018
New qubit now works without breaks: A universal design for superconducting qubits has been created April 19th, 2018
Observing biological nanotransporters: Chemistry April 19th, 2018
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||